MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications

Ruben A.L. de Groen, Anne M.R. Schrader, Marie José Kersten, Steven T. Pals, and Joost S.P. Vermaat

Disclosures: M.J.K. has received honoraria/research funding from Kite Pharma, Millennium/Takeda, Mundipharma, Gilead Sciences, Bristol-Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, and Amgen. The other authors do not have any conflict of interest or disclosure to declare: R.A.G., A.M.S., S.T.P. and J.S.V.

Contributions: R.A.G., A.M.S., S.T.P., M.J.K., and J.S.V. contributed to the design of this review, the interpretation of the literature and the writing of the manuscript.